TOP BIOPHARMACEUTICAL COMPANIES BY REVENUES IN 2021
Revenues in billions
1. JOHNSON AND JOHNSON
Q1 RESULTS
Johnson and Johnson reported sales of $ 22.32 billion in the first quarter of 2021. The company reported growth of 7.9%, operational growth of 5.5%, and 6.0% adjusted operational growth.
Consumer health products contributed $ 3.5 billion, pharmaceuticals contributed $ 12.2 billion, and medical devices grew by $ 6.6 billion.
Stelara sales were $ 2.148 billion, Prezista / Prezcobix / Rezolsta / Symtuza contributed to $ 546 million, Invega Sustenna / Xeplion / Invega Trinza / Trevicta revenues contributed to $ 965 million, Darzalex revenues were $ 1.365 billion, Imbruvica sales were $ 1.125 billion, and Opsumit sales were $ 450 million.
Q2 RESULTS
The company has reported an increase of 27.1% in sales compared to 2020; the company reported revenues of $23.3 billion in the second quarter of 2021. The pharmaceutical sector contributed $12.6 billion, consumer health products added $3.7 billion, and medical devices contributed $6.97 billion.
Stelara sales were $2.27 billion, Tremfya sales were $0.48 billion, Darzalex sales were $1.43 billion, and Opsumit sales were $0.46 billion.
Q3 RESULTS
Johnson and Johnson reported an increase of 10.7% in revenue; the company reported sales of $23.3 billion. The pharmaceutical segment reported sales of $13 billion, an increase of 13.8%. Consumer health sales increased by 5.3% and medical devices by 8.0%.
Q4 REVENUES
Johnson and Johnson reported full-year results; the fourth-quarter revenues were $24.8 billion.
The total revenues of Johnson and Johnson in 2021 are $93.78 billion. The pharmaceutical segment revenues were $50.08 billion, medical devices revenues were $27.06 billion, and consumer health revenues were $14.64 billion.
The company has reported an increase in pharmaceutical revenues by 13.6%, primarily driven by the sales of Darzalex (daratumumab), Stelara (ustekinumab), Imbruvica, and Remicade.
Top selling brands of Johnson and Johnson
2. PFIZER
Q1 RESULTS
Pfizer reported phenomenal results in the Q1 of 2021, primarily because of its COVID19 vaccine. The company reported sales of $14.6 billion; the operational incomes increased by 8%.
COVID19 vaccine revenues were $3.5 billion.
Ibrance revenues were $12 billion, a slight decrease of 1%. Eliquis revenues were $1.6 billion, Xeljan reported sales of $0.45 billion.
FULL YEAR RESULTS
Pfizer reported full year revenues of $81.29 billion.
Best selling products
3. ROCHE
Q1 RESULTS
Roche reported revenues of $ 16.27 billion. The group revenues increased by 3%.
Pharmaceutical revenues decreased by 9%, primarily because of the impact of pandemic and biosimilars.
The group has reported a reduction in sales by CHF 1.6 billion because of the biosimilars of MabThera/Rituxan, Avastin, and Herceptin.
Ocrevus reported sales of CHF 1.2 billion, Perjeta sales were CHF 988 million, Tecentriq sales were CHF 775 million, and Hemlibra sales were CHF 661 million.
H1 RESULTS
The company reported sales of CHF 30.7 billion in the first six months of 2021. The pharmaceuticals revenue dropped by 3%, and diagnostics sales were increased by 51% at CER.
The drop in sales of pharmaceuticals is primarily because of the biosimilars of Avastin and Rituxan; however, the innovative products have driven the sales. Hemlibra revenues increased by 45%, Tecentriq by 29%, and Ocrevus by 23%.
Q3 RESULTS
Roche reported sales of CHF 46.68 billion in the first three months of 2021. The company reported a growth of 8% at a constant exchange rate and 6% in Swiss Francs.
The pharmaceutical sales decreased by 3%; however, the diagnostic sales increased by 38%.
FULL YEAR RESULTS
Roche reported $68.07 billion (CHF 62.80 billion) in 2021. The company has reported an increase of 9% in revenues, pharmaceutical division sales increased by 3%.
Best selling products of Roche
4. ABBVIE
Q1 RESULTS
AbbVie reported an increase in sales by 51%, reported sales of $ 13 billion.
Humira sales were increased by 3.5%; global revenues were $4.87 billion. Skyrizi revenues were %574 million, and Rinvoq sales were $303 million.
Global revenues of Imbruvica were $1.27 billion, and Venclexta was $405 million.
Q4 RESULTS
AbbVie reported revenues of $14.89 billion in Q4 of 2021. In Q4, Humira revenues were $5.33 billion, Imbruvica revenues were $1.39 billion, Skyrizi revenues were $895 million.
FULL-YEAR SALES:
AbbVie reported total sales of $56.20 billion in 2021.
Best selling products of AbbVie are
5. NOVARTIS
Q1 RESULTS
Novartis reported a decline in sales by 2% because of the COVID-19 related forward purchasing. Sandoz sales declined by 13%. The company announced that COVID-19 impacted dermatology, ophthalmology, breast cancer, Sandoz retail, and anti-infectives.
The core operating income was declined by 8%. Net income was decreased by 7%, mainly because of the low operating income. Core operating income reduced by 8%, and core net income declined by 6%.
Cosentyx sales were increased by 11%, reported sales of $ 1.1 billion. Zolgensma sales increased by 81%, with reported sales of $ 319 million. Entresto sales grew by 34%, reported revenues of $789 million, Promacta sales increased by 13% ($ 463 million). Kymriah sales increased by 55% ($ 151 million).
Q2 RESULTS
Novartis reported an increase in revenues by 9%. The pharmaceuticals BU sales grew by 12%, Oncology BU grew by 7%, and Sandoz sales grew by 5%.
Cosentyx sales were $ 1.2 billion (+21%), Entresto sales were $ 0.89 billion (+ 46%), Zolgensma sales were 0.32 billion, Promacta reported sales of 0.5 billion (+18%).
Q3 RESULTS
Novartis reported revenues of $13.03 billion in the third quarter of 2021. Q3 sales grew by 5%. The company reported a growth of 4% in the first nine months. Innovative medicines sales increased by 7%; however, Sandoz sales decreased by 2% because of the increased pricing pressures.
In Q3, Cosentyx sales were $ 1.25 billion, Entresto sales were $ 0.92 billion, Gilenya sales were $ 0.70 billion, and Lucentis sales were $ 0.56 billion.
Q4 RESULTS
Q4 revenues increased by 6%, and reported revenues of $13.29 billion. Cosentyx revenues increased by 13% ($1.24 billion), Entresto increased by 34% (0.95 billion), Kisqali by 58% ($285 million), and Zolgensma by 36% ($342 million).
FULL-YEAR REVENUES:
Novartis reported revenues of $51.63 in 2021, an increase of 4% at the constant currencies rate.
Best selling products of Novartis
6. BMS
Q1 RESULTS
BMS reported $11.1 billion, an increase in sales by 3%.
The sales of Revlimid increased by 1% ($2.94 billion), Eliquis reported sales of $2.89 billion, Opdivo reported $1.72 billion, Orencia sales were $758 million.
7. GSK
Q1 RESULTS
GSK announced sales of £7.4 billion ($10.29 billion). Pharmaceutical revenues were $5.42 billion; vaccine sales were $1.67 billion. Consumer healthcare products reported $3.20 billion.
Dolutegravir products revenues decreased by 15%, reported sales of $1.38 billion. Benlysta sales increased by 18%, with reported sales of $247 million. Established respiratory products sales reduced by 14%, reported sales of $1.57 billion.
Meningitis vaccine sales reduced by 16%, reported sales of $264 million. Shingles vaccine sales were $454.58 million.
Q4 RESULTS
GSK reported revenues of $12.91 billion in Q4 of 2021.
FULL YEAR RESULTS
GSK reported total revenues of $46.27 billion.
8. SANOFI
Q1 RESULTS
Sanofi reported sales of $10.39; sales were reduced by 4.3%.
Dupixent sales increased by 45.6%, with reported sales of $1.27 billion. Aubagio sales were $604 million.
Products indicated for rare diseases contributed to $931 million.
9. MERCK (MSD)
Q1 RESULTS
Merck reported revenues of $12.1 billion, with a decline in sales by a 1% constant exchange rate.
The pharmaceutical division revenues were $10.67 billion. The sales were primarily driven By Keytruda, reporting sales of $3.9 billion, increase 16% at a constant exchange rate.
Other sales drivers were Januvia ($1.3 billion), Gardasil/Gardasil 9 ($917 million).
FULL YEAR RESULTS
Merck reported pharmaceutical division revenues of $42.45 billion in 2021. (Merck's total revenues were $48.70 billion, including the animal health division).
Best selling products of Merck
For pipeline, market overview, and market access reports (syndicate and customized) please write to sales@firstviewinsight.com
For all syndicate reports: Click here
Comments